NRx Pharmaceuticals prices $1.5M public offering of 5M shares at $0.30 per share

NRX Pharmaceuticals, Inc.

Underwritten public offering of 5,000,000 shares of common stock at $0.30/share, gross proceeds approx. $1.5 million.
EF Hutton LLC sole book-runner; underwriters have 45-day option for up to 750,000 additional shares.
Proceeds for working capital and general corporate purposes; may repay convertible note to Streeterville Capital.
Underwriter's warrant issued for up to 250,000 shares at $0.33/share, exercisable after 6 months for 5 years.
Offering closed Feb 28, 2024; 90-day lock-up for directors, officers, and company.

item 1.01 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NRX Pharmaceuticals, Inc. entered into Underwriting Agreement with EF Hutton LLC (effective 2024-02-27).

Action: entry
Agreement: underwriting
Counterparty: EF Hutton LLC
Effective: 2024-02-27

Exact text from the filing

On February 27, 2024, NRx Pharmaceuticals, Inc. (the " Company ") entered into an underwriting agreement (the " Underwriting Agreement ") with EF Hutton LLC (the " Representative "), as the representative of the several underwriters named therein (the " Underwriters "), relating to an underwritten public offering (the " Offering ") of 5,000,000 shares (the " Shares ") of the Company’s common stock, par value $0.001 per share (" Common Stock ").

View on SEC.gov

747 material agreements filed in the last 30 days. Browse all material agreements →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-028788

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.